Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Angioimmunoblastic T-cell Lymphoma: early-phase trial registry
4 of 22 indexed Angioimmunoblastic T-cell Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #756 of 28,707 conditions by registered trial count.
22 US clinical trials · 4 currently recruiting · #756 of 28,707 conditions by registered trial count
Angioimmunoblastic T-cell Lymphoma: 22 US clinical trials tracked, 4 recruiting.
Angioimmunoblastic T-cell Lymphoma is the subject of 22 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 20 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 6 of these trials.
Enrollment posture brief
Registry condition angioimmunoblastic-t-cell-lymphoma
OPEN 4 | RECR 18% | LATE 1 | EARLY 20 | RANK #756 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Adenocarcinoma of the Pancreas (18% recruiting · 11 trials)
Angioimmunoblastic T-cell Lymphoma lists 4 open slots (18% of 22 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Angioimmunoblastic T-cell Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Angioimmunoblastic T-cell Lymphoma is recruiting below its size-band peers.
4 of 22 indexed trials (18.2%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Angioimmunoblastic T-cell Lymphoma research.
National Cancer Institute (NCI) accounts for 6 of 22 trials (27.3%). 14 distinct sponsors appear on at least one study for this condition label.
-
Most Angioimmunoblastic T-cell Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 41 among the 22 trials that report a genuine target (sentinel values excluded). 19 of those (86.4%) plan for fewer than 100 participants.
-
Angioimmunoblastic T-cell Lymphoma research is mostly interventional.
22 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
22 total, page 1 of 1
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Corvus Pharmaceuticals
NCT06561048
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
National Cancer Institute (NCI)
NCT07055477
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
SciTech Development
NCT04234048
Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
National Cancer Institute (NCI)
NCT07388563
Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency
Mayo Clinic
NCT01787409
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
City of Hope Medical Center
NCT03113500
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
Northwestern University
NCT02232516
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
Washington University School of Medicine
NCT05377827
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
Mayo Clinic
NCT00918333
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
University of Chicago
NCT01839916
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
National Cancer Institute (NCI)
NCT01258998
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
Massachusetts General Hospital
NCT00644189
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
National Cancer Institute (NCI)
NCT01326702
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Mayo Clinic
NCT01261247
Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant
Case Comprehensive Cancer Center
NCT01959477
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
University of Washington
NCT00601718
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer
Fred Hutchinson Cancer Center
NCT00006251
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies
Case Comprehensive Cancer Center
NCT01658319
Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
University of Nebraska
NCT01336920
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
NCT00131937
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma
National Cancer Institute (NCI)
NCT00769288
Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
Pierluigi Porcu
NCT01129180
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 14 |
| Phase 2 | 6 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Angioimmunoblastic T-cell Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Angioimmunoblastic T-cell Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Angioimmunoblastic T-cell Lymphoma page
22 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Angioimmunoblastic T-cell Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Angioimmunoblastic T-cell Lymphoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Angioimmunoblastic T-cell Lymphoma condition card totals 22 registered trials; most-linked intervention laboratory biomarker analysis; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.